Source: Annual Congress 2012 - Pulmonary circulation: clinical diagnosis, treatment, end-points and animal models
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Y. Tamura, M. Kuwana, K. Inoue, T. Ono, M. Takei, T. Yamamoto, M. Kataoka, M. Sano, T. Satoh, K. Fukuda (Tokyo, Japan). Human pentraxin 3 (PTX3) as a novel biomarker for the diagnosis of pulmonary arterial hypertension. Eur Respir J 2012; 40: Suppl. 56, 962

Member's Comments

No comment yet.

Related content which might interest you: Endothelin-1 and endothelin-3 plasma levels in severe idiopathic pulmonary arterial hypertension Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology Year: 2005 Plasma nitrite/nitrate levels: a new biomarker for pulmonary arterial hypertension? Source: Eur Respir J 2016; 48: 1265-1267 Year: 2016 Gamma-Glutamyltransferase in pulmonary hypertension: A reliable biomarker? Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension Year: 2020 IL-6 in pulmonary hypertension: why novel is not always best Source: Eur Respir J, 55 (4) 2000314; 10.1183/13993003.00314-2020 Year: 2020 Novel biomarkers in idiopathic pulmonary arterial hypertension Source: Annual Congress 2010 - Pulmonary hypertension Year: 2010 Pentraxin 3 as a novel biomarker of inflammation in chronic obstructive pulmonary disease Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases Year: 2013 The role of the biomarker and the genetic polymorphism of endothelin-1 in pulmonary arterial hypertension among Egyptians Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Inflammatory biomarkers in patients with COPD and pulmonary hypertension (PH). Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension Year: 2019 Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension and their relationship with right ventricular structure and function Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Characteristics of idiopathic pulmonary arterial hypertension (IPAH) and PAH associated with connective tissue disease (APAH-CTD) patients in PROSPECT Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 CXCL12 as a potential disease marker for pulmonary hypertension Source: Annual Congress 2010 - Pulmonary hypertension Year: 2010 Genetics of pulmonary hypertension: from bench to bedside Source: Eur Respir J 2002; 20: 741-749 Year: 2002 Screening for biomarkers in pulmonary hypertension Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and cell biology Year: 2012 Circulating microRNA signature and its novel involvement in pathogenesis of chronic thromboembolic pulmonary hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH Year: 2012 Analysis of miRNA profile in circulating microparticles of patients with pulmonary arterial hypertension Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH Year: 2015 Human β-defensin 2 and interleukin-8 as potential serum markers of pulmonary emphysema Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities Year: 2010 Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases Source: Eur Respir J 2008; 31: 343-348 Year: 2008 The interleukin 13 receptor system is altered in pulmonary arterial hypertension Source: Annual Congress 2006 - Lung vascular and parenchymal remodeling Year: 2006 Expression of fetal genes in pulmonary arterial hypertension Source: Annual Congress 2005 - Pulmonary hypertension and fibrosis: novel mechanisms Year: 2005